INOVIO PHARMACEUTICALS, INC.
No enriched coverage for $INO in the last 7 days.
No SEC Form 4 filings for $INO in the last 30 days.
See all $INO insider activity →Inovio Pharmaceuticals said the FDA completed all scheduled pre-licensure inspections, with one observation addressed. Management reiterated that INO-3107 meets accelerated approval criteria and expects label negotiations in Sept 2026 ahead of an Oct 30 PDUFA. Cash runway extends into late Q1 2027 after a July 2026 $18.3M equity offering; Q3 2026 net cash burn is $18M.
INOVIO (NASDAQ: INO) reported Q2 2026 results and said the FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is progressing toward a PDUFA target date of Oct. 30, 2026. Cash and investments were $36.7M at June 30, 2026. Net loss was $6.0M. ApolloBio reported positive Phase 3 topline results for VGX-3100 in China.
INOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights • U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a tar
Recent INO coverage spans earnings, corporate actions and regulation.
Regulatory inspection completion plus a defined label-negotiation window reduces near-term uncertainty on the accelerated-approval path for INO-3107, while confirmatory-trial protocol feedback remains a key overhang.
Regulatory timeline progress plus cash runway guidance and commercialization prep can re-rate near-term probability of approval and reduce financing overhang.
Near-term catalyst is the FDA review timeline and confirmatory trial feedback, with cash runway extending into late Q1 2027.
This is a scheduled earnings-release event that can drive volatility into and immediately after the August 12 close.
The filing discloses a new equity and warrant issuance structure, which can pressure near-term dilution expectations and funding runway assumptions.
alphai scores every news story that mentions INO with an AI model for sentiment and relevance, and aggregates insider trades from INOVIO PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Inovio Pharmaceuticals said the FDA completed all scheduled pre-licensure inspections, with one observation addressed. Management reiterated that INO-3107 meets accelerated approval criteria and expects label negotiations in Sept 2026 ahead of an Oct 30 PDUFA. Cash runway extends into late Q1 2027 after a July 2026 $18.3M equity offering; Q3 2026 net cash burn is $18M.
6 min readINOVIO (NASDAQ: INO) reported Q2 2026 results and said the FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is progressing toward a PDUFA target date of Oct. 30, 2026. Cash and investments were $36.7M at June 30, 2026. Net loss was $6.0M. ApolloBio reported positive Phase 3 topline results for VGX-3100 in China.
6 min readINOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights • U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a tar
5 min readInovio (NASDAQ: INO) said it will release its second-quarter 2026 financial results after the market close on Aug. 12, 2026. After the release, the company will hold a live conference call and webcast at 4:30 p.m. ET with analyst Q&A and a 90-day replay.
1 min readINOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA – July 29, 2026 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related
4 min readInovio Pharmaceuticals (NASDAQ:INO) shares fell 30.8% in Thursday premarket after the company priced a $20 million underwritten public offering at $0.95 per share. It will sell 21,052,632 shares plus warrants for up to 42,105,264 shares, with warrants priced at a $1.10 exercise price. Piper Sandler is sole manager.
2 min readINOVIO Pharmaceuticals (Nasdaq: INO) priced an underwritten public offering of 21,052,632 shares plus warrants to buy up to 42,105,264 shares, or pre-funded warrants, at a combined price of $0.95 per share and $1.10 warrant exercise price. Gross proceeds are about $20.0 million, excluding option/warrant exercise. Closing expected around July 31, 2026.
2 min readINOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Inovio Pharmaceuticals, Inc. (the “Company”) is providing the following financial information. As of June 30, 2026, the Company estimates that its cash and cash equivalents were approximately $36.7 million. The cash and cas
2 min readWall Street Zen downgraded multiple stocks on June 21, including Predictive Oncology (AGPU) to sell from hold, Agape ATP (ATPC) to sell from hold, Bonk (BNKK) to sell from hold, Columbia Financial (CLBK) to sell from hold, and Camden Property Trust (CPT) to sell from hold. It also cut several ratings to hold or buy for companies such as Devon Energy (DVN), fuboTV (FUBO), and Alnylam (ALNY).
2 min readINOVIO (NASDAQ: INO) said it will participate in upcoming conferences. The company plans a June 4 fireside chat at the Jefferies Global Healthcare Conference in New York, and a June 11 poster presentation at the World Orphan Drug Congress in Boston on next-gen DNA medicine for rare disease protein replacement therapeutics. INOVIO management will also hold one-on-one investor meetings; a 90-day event replay will be available.
1 min read
